SS-31 (elamipretide) is a cardiolipin-binding tetrapeptide that restores mitochondrial structure and ATP production. The timeline below is based on the published clinical trials, human single-dose pharmacology, and what community users consistently report.
Research-context information only. SS-31 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
Two things matter up front. First, SS-31's effects are measurable before they're noticeable — ATP changes are documentable in a lab weeks before anything feels different. Second, the starting point dictates the curve: someone with obvious mitochondrial dysfunction (age-related fatigue, post-viral syndrome, slow recovery) responds faster and more dramatically than someone already near functional ceiling.
Typical community protocol is 500 mcg/day SC, 5 days on / 2 days off, 8 weeks on / 8 weeks off. The timeline below assumes that protocol. For higher clinical trial doses (4-40 mg/day), the shape compresses but direction is the same. Full protocol details in the SS-31 dosing guide.
Timing comes straight out of the pharmacology. SS-31 binds cardiolipin within minutes of reaching mitochondria and concentrates there more than 1,000-fold (Szeto 2014). Plasma half-life is about 16 hours, which is why clinical protocols use once-daily dosing.
The immediate effects — cristae stabilization, ATP recovery — happen in the first hour. The cumulative effects — redox rebalancing, protein S-glutathionylation reversal, exercise capacity gains — build over weeks of repeat dosing (Campbell et al., 2019).
This gives SS-31 an unusual timing profile: very fast acute effects, slow subjective recognition, and clinical endpoints that typically show up in the 12-36 week window seen in Stealth trials.
Day 1: The Acute Dose
What the research shows:
In a randomized trial of 39 older adults with baseline mitochondrial dysfunction, a single IV dose of elamipretide raised in vivo skeletal muscle ATPmax on the day of treatment (Roshanravan et al., 2021).
The elevation faded by day 7, consistent with the 16-hour half-life.
In aged mice, mitochondrial ATP production returned to young-adult levels one hour after a single dose (Siegel et al., 2013).
What users may notice (500 mcg SC, not IV):
Usually nothing the day of the first dose. SC absorption is slower and the dose is much lower than the research IV protocols.
Some users report mild injection-site warmth or a brief subjective energy lift. Most report nothing.
Realistic expectation: Day 1 is a biochemical event, not an experiential one. The first 24 hours is not a meaningful window for evaluating whether SS-31 is working.
No meaningful cardiac biomarker shifts expected in the first week even at trial doses.
What users commonly report:
Slightly steadier afternoon energy (no 2-3pm crash)
Modest improvement in sleep quality — more restorative, fewer wakings
Slightly easier recovery between hard training sessions
Some report faster muscle relaxation after exercise
What users probably will NOT notice:
Major performance gains
Visible cardiovascular or cognitive change
Any measurable body composition movement
Realistic expectation: Week 1 is when mitochondrial machinery is being stabilized. The effects are real but small, and often get attributed to other variables. Users tracking lactate or HRV may start seeing a signal by day 5-7.
Weeks 2-4: First Clinical Changes
What the research suggests:
In the TAZPOWER Barth syndrome trial (40 mg/day), 6-minute walk and symptom score primary endpoints at week 12 were not met in the randomized phase — meaning clinically detectable functional change is modest at 3-6 weeks even at full clinical dose (Thompson et al., 2021).
In MMPOWER-1 for primary mitochondrial myopathy, 6-minute walk improvements showed up within the short dose-escalation window (Karaa et al., 2018).
Mouse data consistently show exercise tolerance and redox improvements by 1-2 weeks of daily dosing (Campbell et al., 2019).
What users commonly report:
Noticeably better workout recovery — less DOMS, faster return to baseline
Clearer afternoon cognitive stability (anecdotal, not well-studied)
Some skin quality reports (often attributed to reduced oxidative stress, limited evidence)
For users with documented fatigue syndromes, first subjective "lift" often lands here
More consistent baseline energy throughout the day
What users probably will NOT notice:
Dramatic endurance gains (those come later if at all)
Vision change — AMD trials show effect at 24-48 weeks, not 2-4
Realistic expectation: This is the window where most community users first say "yeah, I think it's doing something." When week 4 still brings no subjective change, community sources commonly check the dosing guide for reconstitution and storage issues — or run the week-4 bloodwork panel.
Month 2: Biomarker Shifts
What the research suggests:
In aged muscle, SS-31 reverses pathological S-glutathionylation across hundreds of proteins, with glutathione redox status moving to a more reduced state (Campbell et al., 2019).
Structural mitochondrial remodeling — not just acute ATP rescue — starts becoming detectable in this window in animal models.
Fasting lactate is the most accessible human marker that responds to improving mitochondrial efficiency; many community users see 0.2-0.5 mmol/L reductions by week 6-8.
What users commonly report:
Clear endurance gains during cardio work — longer threshold sessions, lower RPE at the same pace
Realistic expectation: Month 2 is where objective evidence catches up with subjective reports. This is the best window to pull labs and make a stay/stop decision based on data, not feel.
Months 3-6: Structural Remodeling
What the research suggests:
The TAZPOWER 168-week open-label extension showed sustained improvements in cardiac function and exercise capacity that kept building past 36 weeks (Thompson et al., 2021).
The ReCLAIM-2 AMD trial ran 48 weeks, with ellipsoid zone preservation effects visible at study endpoint (Allingham et al., 2024).
Preclinical work suggests mitochondrial biogenesis and remodeling (not just rescue) emerges after 8-12 weeks of continuous treatment.
What users commonly report:
Endurance gains that persist even on off-cycle weeks
Fewer "bad energy days" — higher floor rather than higher peak
Sleep quality stabilization
Mild cognitive improvements in users who started with subjective brain fog
For older users (55+): sustained reduction in age-related fatigue complaints
What users probably will NOT see:
Anything resembling an anabolic effect
Dramatic AMD/vision change at community doses (trial dose was 80x community dose)
Cardiac remodeling in the absence of baseline cardiolipin pathology
Realistic expectation: Months 3-6 separate responders from non-responders. In responders, the gains plateau but persist. In non-responders, the absence of signal is clear by now — no hidden late bloom.
Bac Water Made for Peptides50% off
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
Age matters: Older adults with documented mitochondrial dysfunction are the population SS-31 is most clearly effective in (Roshanravan et al., 2021, Siegel et al., 2023). Under-40 users frequently report minimal subjective benefit.
What SS-31 Will NOT Do
No hypertrophy. SS-31 restores mitochondrial function; it doesn't drive muscle growth.
No fat loss. No controlled data supports a body-composition effect.
No acute performance boost. For pre-workout energy, SS-31 is the wrong tool.
No universal response. The MMPOWER-3 subgroup analysis suggests some genetic backgrounds don't respond.
No replacement for sleep, nutrition, or training. It rescues dysfunction; it doesn't compensate for lifestyle deficits.
When to Adjust or Stop
Community sources commonly continue the cycle when:
Week 4 bloodwork shows lactate decrease or any oxidative stress marker improvement
Subjective energy, recovery, or sleep has moved in the right direction
SS-31 is being used for a specific indication (cardiac, AMD) with baseline dysfunction
Community sources commonly stop or switch when:
Week 8 arrives with no subjective or biomarker change
Injection-site reactions persist beyond first week
An under-40, highly trained user sees zero signal by week 6 — SS-31 may not be the right tool; MOTS-c is a signaling-pathway alternative
Community protocols cycle off regardless at 8 weeks. This gives mitochondrial adaptation time to stabilize and prevents potential desensitization. See the SS-31 vs MOTS-c comparison for the rotation logic.
Frequently Asked Questions
How fast does SS-31 work?
Measurable mitochondrial changes happen within hours of a single dose, but most users don't notice subjective effects until days 7-14. Clinical biomarker shifts (lactate, oxidative stress) typically show up by week 4-6.
What should I feel in week 1 of SS-31?
Often nothing dramatic. Some users report slightly better sleep quality, modestly easier workout recovery, or steadier afternoon energy by day 5-7. Anyone claiming major first-week changes is usually describing placebo or expectation bias.
When should I retest bloodwork on SS-31?
Baseline before starting. First retest at week 4-6 for fasting lactate, CoQ10, and oxidative stress markers. Full retest 2-4 weeks after finishing the 8-week cycle to see whether changes persist.
Do Barth syndrome or heart failure trial timelines apply to community use?
Partially. The TAZPOWER trial used 40 mg/day IV in genetic cardiolipin deficiency — 80x the community dose. The time course (subtle early, clearer by 12+ weeks, sustained at 36+ weeks) is still a useful reference shape even at lower doses.
What if I feel nothing after 4 weeks?
First check consistency, dose, and storage. With 500mcg/day SC held at proper refrigeration for 4 weeks and no subjective or lab change, the individual may be someone whose mitochondrial function is already near ceiling — or whose dysfunction isn't cardiolipin-centered. Community sources commonly stop or switch to MOTS-c at that point.
How long should results last after stopping SS-31?
The single-dose ATP effect faded by day 7, tracking the 16-hour plasma half-life. With repeat dosing over 8-12 weeks, functional gains tend to persist 2-4 weeks after stopping before trending back toward baseline. Most community protocols cycle 8 weeks on, 8 weeks off for this reason.
Research Supplies for SS-31 (Elamipretide)
Hand-picked storage, injection, and recovery supplies paired with SS-31 (Elamipretide) protocols.
For educational and research purposes only. This is not medical advice. SS-31 (elamipretide) is FDA-approved for Barth syndrome as of 2025; all other uses remain investigational. Timeline reflects typical community protocols and published clinical data — individual results vary.
